環境中の毒素ビブリオ・コレラエ

A Medium for Presumptive Identification of Vibrio parahaemolyticus.

Journal of food protection·2019

Vibrios in the Louisiana gulf coast environment.

Microbial ecology·2013

LEE-encoded regulator (Ler) mutants elicit serotype-specific protection, but not cross protection, against attaching and effacing E. coli strains.

Vaccine·2007

Second-generation recombination-based in vivo expression technology for large-scale screening for Vibrio cholerae genes induced during infection of the mouse small intestine.

Infection and immunity·2005

Enzyme-linked immunosorbent assay for detection of Shiga toxin-producing Escherichia coli infection by antibodies to Escherichia coli secreted protein B in children with hemolytic uremic syndrome.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2004

Cloning, expression and characterization of the CHO cell elongating factor (Cef) from Vibrio cholerae O1.

Microbial pathogenesis·2002

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Mechanistic insights into PM<sub>2.5</sub>-induced cardiac fibrosis involving ERS/TXNIP/NLRP3-driven pyroptosis in multiple cell types.

Environmental epigenetics·2026

Disruption of Lysosomal Homeostasis Following Combined Exposure to Lead and Amyloid-β Peptides (25-35) and (1-40) in SH-SY5Y Cells.

Journal of applied toxicology : JAT·2026

The Role of Microbiota, Gut Integrity, and Neuroinflammation in Relapse Vulnerability in Alcohol Use Disorder.

Current neuropharmacology·2026

Association of PM<sub>2.5</sub> chemical components with metabolome and peak expiratory flow in patients with stable COPD: a panel study.

Respiratory research·2026

Coral metabolome quality and contaminant loads track human land use.

Nature communications·2026

Contribution of Consumer Products to Emerging Chemical Exposures in a Preconception Cohort Study.

Environmental science & technology·2026

関連する実験動画

環境中の毒素ビブリオ・コレラエ

関連する概念動画

A Medium for Presumptive Identification of Vibrio parahaemolyticus.

Vibrios in the Louisiana gulf coast environment.

LEE-encoded regulator (Ler) mutants elicit serotype-specific protection, but not cross protection, against attaching and effacing E. coli strains.

Second-generation recombination-based in vivo expression technology for large-scale screening for Vibrio cholerae genes induced during infection of the mouse small intestine.

Enzyme-linked immunosorbent assay for detection of Shiga toxin-producing Escherichia coli infection by antibodies to Escherichia coli secreted protein B in children with hemolytic uremic syndrome.

Cloning, expression and characterization of the CHO cell elongating factor (Cef) from Vibrio cholerae O1.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Mechanistic insights into PM<sub>2.5</sub>-induced cardiac fibrosis involving ERS/TXNIP/NLRP3-driven pyroptosis in multiple cell types.

Disruption of Lysosomal Homeostasis Following Combined Exposure to Lead and Amyloid-β Peptides (25-35) and (1-40) in SH-SY5Y Cells.

The Role of Microbiota, Gut Integrity, and Neuroinflammation in Relapse Vulnerability in Alcohol Use Disorder.

Association of PM<sub>2.5</sub> chemical components with metabolome and peak expiratory flow in patients with stable COPD: a panel study.

Coral metabolome quality and contaminant loads track human land use.

Contribution of Consumer Products to Emerging Chemical Exposures in a Preconception Cohort Study.

関連する実験動画

環境中の毒素 ビブリオ・コレラエ

関連する概念動画

関連記事

環境中の毒素ビブリオ・コレラエ